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http://dx.doi.org/10.1016/j.jacl.2016.05BACKGROUND: The efficacy and safety of atorvastatin in children/adolescents aged 10–17 years
with heterozygous familial hypercholesterolemia (HeFH) have been demonstrated in trials of up to
1 year in duration. However, the efficacy/safety of .1 year use of atorvastatin in children/adolescents
with HeFH, including children from 6 years of age, has not been assessed.
OBJECTIVE: To characterize the efficacy and safety of atorvastatin over 3 years and to assess the
impact on growth and development in children aged 6–15 years with HeFH.
METHODS: A total of 272 subjects aged 6–15 years with HeFH and low-density lipoprotein choles-
terol (LDL-C) $4.0 mmol/L (154 mg/dL) were enrolled in a 3-year study (NCT00827606). Subjects
were initiated on atorvastatin (5 mg or 10 mg) with doses increased to up to 80 mg based on LDL-C
levels.
RESULTS: Mean percentage reductions from baseline in LDL-C at 36 months/early termination
were 43.8% for subjects at Tanner stage (TS) 1 and 39.9% for TS $2. There was no evidence of var-
iations in the lipid-lowering efficacy of atorvastatin between the TS groups analyzed (1 vs $2) or in
subjects aged ,10 vs $10 years, and the treatment had no adverse effect on growth or maturation.
Atorvastatin had a favorable safety and tolerability profile, and only 6 (2.2%) subjects discontinued
because of adverse events.
CONCLUSIONS: Atorvastatin over 3 years was efficacious, had no impact on growth/maturation,
and was well tolerated in children and adolescents with HeFH aged 6–15 years.
 2016 National Lipid Association. Published by Elsevier Inc. This is an open access article under the CC
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c, Oslo University Hospital, Post
.
cepted for publication May 28,
ociation. Published by Elsevier Inc. Th
d/4.0/).
.010Introduction
Elevated cholesterol levels in childhood are associated
with an increased incidence of atherosclerosis in adult-
hood.1,2 The severity of atherosclerosis can be correlated tois is an open access article under the CC BY-NC-ND license (http://
1154 Journal of Clinical Lipidology, Vol 10, No 5, October 2016the extent and duration of hypercholesterolemia.3 Familial
hypercholesterolemia (FH) is a common inherited auto-
somal dominant disorder of lipoprotein metabolism charac-
terized by reduced clearance of low-density lipoprotein
cholesterol (LDL-C) from the circulation leading to
elevations of LDL-C.4,5 In most cases (85%–90%), FH is
caused by defects in the low-density lipoprotein-receptor
(LDL-R) gene. Defects in the genes for apolipoprotein B
(apoB) and proprotein convertase subtilisin/kexin type 9 ac-
count for about 5% and ,5% of cases, respectively.4
Rarely, autosomal recessive hypercholesterolemia can
cause FH.6,7 In most populations, heterozygous familial
hypercholesterolemia (HeFH) affects w1 in 200–250 indi-
viduals.8 FH is associated with increased morbidity of
coronary heart disease and with premature death8–11, and
children with FH have greater carotid intima media thick-
ness than their unaffected siblings.12,13
Early intervention with cholesterol-lowering treatment,
primarily statins, has been shown to prevent early coronary
heart disease.14–16 The evidence base for the efficacy and
safety of statins in children is growing.17–28 However,
gaps in this evidence base remain.29 For example, studies
conducted with atorvastatin in children/adolescents with
HeFH were up to 1 year in duration with the impact on
growth/development evaluated at 26 weeks.26 Furthermore,
the 1-year study was conducted in children/adolescents of
10–17 years,26 whereas statins are now considered in chil-
dren with HeFH ,10 years.5 This 3-year study enrolling
w250 subjects aged 6–15 years with genetically confirmed
HeFH was therefore conducted to characterize the long-
term efficacy and safety of atorvastatin and to assess the
impact of this medication on growth and development.
Also, as part of this work, we examined the impact of ator-
vastatin treatment on endothelial function in the brachial ar-
teries assessed by flow-mediated dilation (FMD).30 This
was an optional exploratory study to assess the potential
for a change in the FMD to act as a surrogate biomarker
for the efficacy of LDL-C lowering as previously shown
in a study with simvastatin therapy in children and adoles-
cents with FH.31Methods
Standard protocol approvals, registrations, and
patient consents
This open-label, multicenter, prospective study was
conducted between March 30, 2009 and October 8, 2013
at 30 centers across 14 counties in compliance with the
Declaration of Helsinki and International Conference on
Harmonization Good Clinical Practice guidelines. In addi-
tion, all local regulatory requirements were followed. The
protocol and the informed consent documents were re-
viewed and approved by the institutional review boards
and/or independent ethics committees at each participatingcenter. Parents or legal guardians provided informed con-
sent. The subject could also sign a written consent form, if
they were able to do so. The exact processes and procedures
for attaining assent and consent varied between countries.
However, all country-specific guidelines were complied
with.
Study population
Girls and boys aged 6–15 years with genetically
confirmed HeFH (those girls and boys who had no prior
record of genetically confirmed HeFH underwent genetic
testing pre-randomization to confirm whether they had
HeFH). DNA was extracted from saliva or from blood, and
the 18 exons and flanking regions of the LDL-R gene and
exon 26 of the apoB gene were sequenced using SANGER
methodology. Samples were also tested for large deletions
or insertions in the LDL-R gene, using Multiplex Ligase-
dependent Probe Amplification (MLPA) analysis (Details
provided in Supplementary Material).
All those who did not have genetically confirmed HeFH
were excluded. All patients also had to have an LDL-C of
$4.0 mmol/L (154 mg/dL) for inclusion. Exclusion criteria
included a history of active liver disease, hepatic dysfunc-
tion, or persistent elevations of serum transaminases
.3! the upper limit of normal (ULN) or conditions likely
to delay puberty. Pregnant or breastfeeding females, and
females of childbearing potential not using adequate
contraception, were excluded. Subjects with hypersensitiv-
ities to statins or receiving statin therapy within 4 weeks of
randomization were excluded. However, a 4-week washout
of lipid-lowering medication was permitted.
Study design
The doses of atorvastatin used in this study were based
on the results of a study comparing the efficacy and safety
of different starting doses of atorvastatin in adults with
dyslipidemia32 and earlier studies conducted in 6–17-year-
old subjects.21,26
In total, 272 subjects with HeFH were stratified into 2
cohorts according to their Tanner stage (TS) (1 or $2) at
screening. Subjects aged 6 to ,10 years (mostly TS 1)
initiated therapy on atorvastatin 5 mg per day (a pediatric
chewable formulation), and those aged 10 to 15 years
(mostly TS $ 2) initiated treatment with atorvastatin 10 mg
per day.
Subjects had their dose titrated based on an LDL-C
target of ,3.35 mmol/L (,130 mg/dL). Doses were
increased from 5 to 10 to 20 mg or 10 to 20 to 40 mg
per day. Titrations above 40 mg per day were permitted
after discussions with the study sponsor. Subjects initiating
treatment on atorvastatin 10 mg per day were permitted to
decrease their dose if their LDL-C decreased to
,2.59 mmol/L (100 mg/dL). Subjects with LDL-C
,2.59 mmol/L on the 5 mg dose were discontinued.
Langslet et al Atorvastatin therapy in children and adolescents 1155Atorvastatin was dispensed at visit 1 (day 0), and subjects
were seen monthly until month 6 at which point they were
seen every 6 months. TS assessments were made at
screening and every 6 months.
Outcome assessments
The primary assessments were measures of growth and
development (height, weight, body mass index [BMI], TS),
efficacy (absolute and percentage change from baseline in
LDL-C, total cholesterol [TC], triglycerides [TG], high-
density lipoprotein cholesterol [HDL-C], apo A-1, apoB),
tolerability, and safety. An exploratory secondary efficacy
endpoint was change from baseline in FMD in a subset of
subjects (see Supplemental Information). Subjects were
required to fast for $10 hours before the collection of sam-
ples for lipid assessments. The incidence, severity, and po-
tential causal relationship of treatment-emergent adverse
events (AEs) were monitored alongside abnormal labora-
tory findings. Hematology, blood chemistry, and urinalysis
were also evaluated at screening and throughout the study.
AEs were classified as mild (does not interfere with sub-
ject’s usual function), moderate (interferes to some extent
with subject’s usual function), or severe (interferes signifi-
cantly with subject’s usual function).
Statistical analysis
The full analysis set, defined as all subjects who
received $1 doses of the study drug, was included in all
analyses. No imputations were used for missing values.
Subjects were categorized by TS 1 or $2 for analyses of
lipid endpoints and safety/tolerability, and also by age
,10 years and $10 years for some analyses. Height,
weight, BMI and FMD were analyzed by gender. Analyses
were performed using descriptive statistics. Demographic
and baseline data were summarized as mean 6 standard
deviation (SD) for continuous variables. The mean dose of
atorvastatin was calculated as the average dose per subject
weighted by duration on each dose and the unweighted
average calculated regardless of the duration on each dose
and the mean maximum dose. The percentage of subjects
receiving 5, 10, 20, 40, or 80 mg atorvastatin as their
maximum dose stratified by TS and age was calculated. The
percentage of subjects who attained an LDL-C goal of
,3.35 mmol/L (,130 mg/dL) at each visit was also
calculated.Results
Study population
A total of 400 pediatric subjects were screened and 272
with a genetically confirmed diagnosis of HeFH were
enrolled (87 subjects without a previously confirmedgenetic diagnosis of HeFH were considered for genetic
screening and 66 were screened of which 49 [74.2%] were
confirmed positive for HeFH) (Fig. 1). This study was con-
ducted at 30 centers worldwide, and the methodologies for
genetic testing and the manner in which this information
was collated differed both between centers and the central
laboratory used to screen the patients without confirmed
FH. Therefore, unfortunately, it has not been possible to
collate this information for patients across the study. One
subject was assigned to study treatment, but not treated,
due to a protocol violation. The 271 subjects treated
comprised 139 children at TS 1 and 132 adolescents at
TS $2.
Overall, 206 subjects (76.0%) completed the study with
65 (24%) discontinuing. In subjects at TS1, the most
frequent cause of discontinuation was no longer being
willing to participate in the study, whereas for subjects at
TS $2, the most common reason for discontinuation was
‘‘low LDL-C’’ (defined as LDL-C ,2.59 mmol/L [100 mg/
dL] in subjects receiving atorvastatin 5 mg; 12 subjects).
Unfortunately, in some cases, investigators were unaware
that subjects initiating treatment on 10 mg per day could be
down-titrated to 5 mg per day; this knowledge may have
prevented some of these discontinuations.
The mean age of children at TS 1 at baseline was
8.5 years (SD 5 1.9), the majority were male (66.9%) and
white (96.4%; Table 1). The adolescents at TS $2 at base-
line had a mean age of 12.0 years (SD 5 1.7), the majority
were female (59.8%) and white (98.5%). Overall, 27.3% of
subjects were aged 6–8 years, and 51.7% were aged
#10 years at baseline.
The mean weighted and mean maximum doses were
similar in the subjects at TS 1 and $2, whereas mean doses
were consistently higher in the subjects aged $10 years vs
those aged ,10 years (Fig. 2A). Few subjects (18, 6.6%)
received atorvastatin 80 mg during the study, and 12 sub-
jects (8.6%) at TS 1 received this maximum dose
(Fig. 2B). The median duration of treatment was
1085 days (interquartile range [IQR], 1035.0–1099.0) over-
all for all subjects, 1084.0 days (IQR, 1060.0–1099) for TS
1 and 1085.0 (IQR, 634.0–1099.35) for TS $2. Approxi-
mately 70% of subjects received concomitant medications,
most commonly ibuprofen and paracetamol (Supplemental
Table 1).
Efficacy
There was very little difference in the mean percentage
changes from baseline in LDL-C in all subjects and those at
TS 1 or $2 over the study duration (Fig. 3 and Table 2).
Mean LDL-C levels were reduced by w35% from month
1 in all subject groups, with a further reduction to w45%
at month 3. LDL-C levels were then maintained at this level
to month 30. At month 36/early termination, the mean
reduction in LDL-C in the TS 1 group remained at
243.8%, whereas in the TS $2 group, it decreased to
239.9%.
Cohort Cohort 
Cohort 0
Subjects screened
400
Cohort 
Cohort 
Cohort Completed 112 (80.6%)Discontinued 27 (19.4%)
Assigned to study
        treatment
             272
Completed 94 (71.2%)
Discontinued 38 (28.8%) 
TS ≥2
Atorvastatin 10 mg
Allocated 132
Treated  132
TS 1
Atorvastatin 5 mg
Allocated 140
Treated 139
Reasons for discontinuation: 
Lost to follow-up 3 (2.2%)
No longer willing 7 (5.0%)
Protocol violation 4 (2.9%)
Low LDL-C* 4 (2.9%)
AE related to study drug 3 (2.2%)
AE not related to study drug 1 (0.7%)
Other 5 (3.6%)
Cohort 0
Reasons for discontinuation: 
Lost to follow-up 1 (0.8%)
No longer willing 6 (4.5%)
Protocol violation 3 (2.3%)
Low LDL-C* 12 (9.1%)
AE related to study drug 2 (1.5%)
Pregnancy 1 (0.8%)
Other 13 (9.8%)
Figure 1 Patient disposition. AE, adverse event; LDL-C, low-density lipoprotein cholesterol; TS, Tanner stage. *LDL-C ,2.59 mmol/L
(100 mg/dL).
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LDL-C target of ,3.35 mmol/L (130 mg/dL) at month 3,
and goal attainment remained above 50% for the duration
of the study, peaking at 67.4% at month 18. For the age
$10 years’ cohort, 52% of subjects achieved this goal at
month 2, and goal attainment remained above 50% for the
duration of the study, peaking at 78% at month 30 (Fig. 4).
The mean percentage reductions from baseline at month
36/early termination in TC, non–HDL-C, and apoB were
comparable for subjects at TS 1 and TS $ 2 (Fig. 5 and
Table 2). HDL-C levels decreased slightly (1.1%) from
baseline at month 36/early termination in subjects at TS 1
and increased slightly (1.6%) in subjects at TS $ 2. Base-
line TG levels were slightly higher in the TS $2 group
when compared with the TS 1 group (0.980 vs
0.880 mmol/L [86.8 vs 77.9 mg/dL], respectively). A larger
mean percentage reduction in TG level at month 36/early
termination was observed in the TS $2 group than in the
TS 1 group (27.76% vs 20.70%). A modest reduction inapo-A1 levels was reported for both TS groups (24.80%
vs 21.95% for TS 1 and TS $2 at month 36/early termina-
tion, respectively).
Flow-mediated dilation
The FMD profile showed no discernable trends in either
male or female subjects (See Supplemental Information).
Development and growth
At the month 36/early termination visit, male subjects
had increased in height from baseline by a mean of 11.0%
vs a mean of 8.1% for female subjects. The mean height in
female subjects increased from 145 cm (mean age,
10.6 years) at baseline to 157 cm (mean age, 13.1 years)
at month 36/early termination. The mean height in male
subjects increased from 144 cm (mean age, 9.9 years) to
161 cm (mean age, 12.7 years) at month 36/early
Table 1 Demographics and baseline characteristics
Characteristic
TS 1, Total
(n 5 139)
TS $2, Total
(n 5 132)
Age, y, n (%)
6–8 69 (49.6) 5 (3.8)
9–10 45 (32.4) 21 (15.9)
11–14 25 (18.0) 104 (78.8)
15–15 0 2 (1.5)
Mean 8.5 12.0
SD 1.9 1.7
Range 6–12 8–15
Gender, Male, n (%) 93 (66.9) 53 (40.2)
Race
White 134 (96.4) 130 (98.5)
Black 1 (0.7) 1 (0.8)
Asian/other 4 (2.9) 1 (0.8)
Weight, kg
Mean 33.8 49.4
SD 11.3 12.1
Range 17–75 26–82
BMI, kg/m2
Mean 18.1 20.3
SD 3.7 3.7
Range 12.6–30.7 13.8–33.7
Height, cm
Mean 135.0 155.1
SD 12.1 10.5
Range 109–162 132–184
Baseline LDL-C, mmol/L (mg/dL)
Mean 6.30 (243.62) 5.92 (228.93)
SD 1.31 (50.66) 1.16 (44.86)
BMI, body mass index; LDL-C, low-density lipoprotein cholesterol;
SD, standard deviation.
To convert mmol/L to mg/dL multiply by 38.67.
Figure 2 (A) Mean unweighted, weighted, and maximum doses
of atorvastatin received by children and adolescents with HeFH
stratified by TS and age. (B) The percentage of subjects receiving
atorvastatin 5, 10, 20, 40, or 80 mg as their maximum dose, all
subjects, by TS and age. HeFH, heterozygous familial hypercho-
lesterolemia; SE, standard error; TS, Tanner stage.
Langslet et al Atorvastatin therapy in children and adolescents 1157termination. At the month 36/early termination, male
subjects had increased in weight from baseline by a mean
of 32.5% compared with 27.3% for female subjects.
The shift in TS over this 3-year study is shown in
Figure 6. By month 36/early termination visit just 41 of 253
subjects (16.2%) were at TS 1 in comparison with 139 of
271 (51.3%) at baseline. Conversely, the percentage of sub-
jects at TS 5 increased from 6.6% (18 of 271) at baseline to
25.3% (64 of 253) at study end.
Safety
The overall incidence of all-causality AEs was very
similar in the TS 1 (81.3%) and TS $2 (79.5%) groups
(Table 3). Most AEs were of mild or moderate intensity.
There were no deaths. Overall, 21 patients (7.7%) reported
a serious AE (SAE). Overall, 6 (2.2%) subjects discontin-
ued because of AEs (Table 3). This included 4 subjects at
TS 1 (1 subject experienced Ewing’s sarcoma, 1 increase
in blood bilirubin, 1 intravascular papillary endothelial hy-
perplasia, and 1 subject experienced abdominal pain,constipation, fatigue, and headache), and 2 subjects at
TS $ 2 (1 subject experienced myalgia and 1 eosinophilia).
A total of 24 (8.9%) subjects had their dose reduced or
temporarily discontinued because of treatment-related
AEs. All the treatment-related AEs were mild or moderate
in intensity. The most commonly occurring all-causality
AEs are shown in Table 3.
Of the subjects with a SAE, 14 were from the TS 1
group, and 7 were from the TS $2 group (see
Supplemental Information for full details of these SAEs).
A single SAE considered to be treatment-related by the
investigator was reported: a 9-year-old male receiving ator-
vastatin 80 mg experienced an SAE of Ewing’s sarcoma on
day 704 of the study. The subject was hospitalized as a
result of this condition. There was no evidence of dose-
related increase in the overall incidence of AEs or discon-
tinuations/dose reduction of study medication
(Supplemental Tables 2 and 3).
There were no obvious trends, or dose-related trends, in
the incidence of laboratory abnormalities. No subjects had
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Figure 3 Mean percentage change from baseline in LDL-C in
all subjects with HeFH and by TS 1 and $2 and aged ,10 and
$10 years at baseline. HeFH, heterozygous familial hypercholes-
terolemia; LDL-C, low-density lipoprotein cholesterol; TS, Tanner
stage.
1158 Journal of Clinical Lipidology, Vol 10, No 5, October 2016aspartate aminotransferase or alanine aminotransferase
levels .3! ULN. Overall, 23 subjects (8.6%) had creatine
kinase (CK) of .2! ULN. The incidence of this
abnormality was much greater in the TS $ 2 (17; 12.9%)
than in the TS 1 group (6; 4.4%). One subject, a 14-year-
old male, was reported with increased CK (10! ULN) as a
SAE. This was thought to be related to hard physical
exercise. Elevations in CK were observed in other male
subjects after intense exercise and in both genders after
viral infections. All the other AEs related to laboratory
abnormalities were of mild or moderate intensity.Ta
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d.Discussion
This 3-year, open-label, prospective study enrolling very
young subjects with HeFH demonstrated that atorvastatin
was well tolerated and efficacious in children and adoles-
cents (6–15 years at study entry). Furthermore, there was no
evidence that treatment with atorvastatin had any clinically
relevant effect on growth or maturation. Because endoge-
nous steroid hormone production is derived from choles-
terol, a potential concern is how statin therapy may affect
sexual development in children and adolescents.33 An
earlier study demonstrated that treatment with lovastatin
(20–40 mg/day) for 24 weeks had no effect on hormone
levels or menstrual cycle length in adolescent girls with
HeFH aged 10–17 years.19
The TS shift from baseline during our 3-year trial was
consistent with the normal trajectory for maturation and
development. For example, movement to TS 2 occurs from
age 11 years (range, 8–13 years) in females and slightly
later in males (range, 9.5–13.5 years), and TS 5 is usually
reached at 14–15 years in females (range, 13–18 years) and
15 years in males (range, 13.5–17 years).34,35 Furthermore,
the mean height of both male and female subjects was
above the 0 z-score lines on the gender-specific WHO
height for age charts.36,37 The mean height in males
1 2 3 6 12 18 24 30 36
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Age ≥10 years (n = 121-158)
Total (n = 206-261)
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Figure 4 Percentage of subjects aged,10 years or$10 years at
baseline achieving LDL-C goal of ,3.35 mmol/L (,130 mg/dL)
at each study visit. LDL-C, low-density lipoprotein cholesterol. Figure 6 Changes in the percentage of subjects in each TS over
36 months/early termination among children and adolescents with
HeFH receiving atorvastatin therapy. HeFH, heterozygous familial
hypercholesterolemia; TS, Tanner stage.
Langslet et al Atorvastatin therapy in children and adolescents 1159followed the 1 z-score line. In both males and females, the
mean increase in height over the 3-year study followed the
same trajectory as this reference group.
There is increasing evidence that the administration of
statins early in life is beneficial in preventing or reducing
atherosclerosis in subjects with FH.8,38 In this study, we
observed that atorvastatin administration led to substantial
reductions in LDL-C and other atherogenic lipid parame-
ters. The reductions in LDL-C reached maximal levels of
w45% at months 3 to 6 and then remained at this level
throughout the follow-up period. There was a slight in-
crease in LDL-C at month 36/early termination, possibly
due to the inclusion of data from subjects who discontinued
study medication early in the trial. Substantial reductions at
month 36/early termination were also observed in apo B
and non-HDL-C. There appeared to be no evidence of var-
iations in the lipid-lowering efficacy of atorvastatinFigure 5 Mean percentage change from baseline in lipid param-
eters at month 36/early termination in all subjects with HeFH and
by TS 1 and $2 at baseline. Apo, apolipoprotein; HDL-C, high-
density lipoprotein cholesterol; HeFH, heterozygous familial hy-
percholesterolemia; TC, total cholesterol; TG, triglyceride; TS,
Tanner stage.between the TS groups analyzed (1 vs $2) or in subjects
aged ,10 vs $10 years.
The reductions of LDL-C observed are in accordance
with the findings from other clinical studies conducted in
pediatric and adolescent populations in which atorvastatin
and other statins have been administered.17,19–26,28 More-
over, the early efficacy of atorvastatin in this study is
consistent with that observed in a similar but smaller
(n 5 39) short-term (8-week) atorvastatin study in which
doses of 5–20 mg per day were administered to children
and adolescents with HeFH. In the small 8-week study,
mean LDL-C reductions from baseline of 40.7% and
39.7% were observed at week 8 in subjects at TS 1 and
$2, respectively.21 Similar reductions in LDL-C (40%)
were observed at week 26 in a larger study (n 5 187) in
which atorvastatin (10–20 mg per day) was administered
to children and adolescents with FH or severe hypercholes-
terolemia.26 The slightly greater reductions in LDL-C
observed in this (w45%) vs the earlier studies (w40%)
might be related to the higher doses of atorvastatin
permitted in this study (up to 80 mg per day).
Atorvastatin was shown in this 3-year study to have a
favorable safety and tolerability profile. Only 6 (2.2%)
patients discontinued because of AEs. Regarding the SAE
of Ewing’s sarcoma in a 9-year-old male receiving
atorvastatin 80 mg, evidence that this was not associated
with statin use comes from a meta-analysis of 26 clinical
trials of statin therapy, containing over 170,000 partici-
pants, which demonstrated no increase in cancer incidence
among subjects receiving statins.39 Also, the etiology of
Ewing’s sarcoma suggests that it is very unlikely that the
atorvastatin treatment was associated with this cancer.
No unexpected or new safety findings were observed
despite 27.3% of the children enrolled being 6–8 years and
51.7% ,10 years at the start of the study. The differences
in AEs and treatment-related AEs were not considered to be
Table 3 The percentage of subjects* reporting all-causality and treatment-related AEs, discontinuations because of AEs, and the most
commonly reported AEs by TS and overall
Type or category of AE TS 1 (n 5 139) TS $2 (n 5 132) Total (n 5 271)
Subjects with AEs 81.3, 40.3 79.5, 37.1 80.4, 38.7
Serious AEs 10.1, 0.7 5.3, 0 7.7, 0.4
Discontinued because of AE 2.9, 2.2 1.5, 1.5 2.2, 1.8
Dose of study medication reduced or temporarily discontinued 18.7, 7.9 15.2, 9.8 17.0, 8.9
Most frequently occurring AEs ($10% all causality in any group)
Nasopharyngitis 18.7, 3.6 19.7, 5.3 19.2, 4.4
Headache 18.0, 7.9 18.9, 6.8 18.5, 7.4
Abdominal pain 15.1, 9.4 7.6, 4.5 11.4, 7.0
Upper respiratory tract infection 14.4, 3.6 7.6, 1.5 11.1, 2.6
Gastroenteritis 12.2, 2.2 9.1, 0.8 10.7, 1.5
Pyrexia 10.8, 1.4 9.8, 3.0 10.3, 2.2
Influenza 9.4, 0 10.6, 0 10.0, 0
Cough 10.1, 2.9 8.3, 3.0 9.2, 3.0
Vomiting 10.8, 2.9 6.1, 4.5 8.5, 3.7
Pain in extremity 10.1, 4.3 3.8, 3.0 7.0, 3.7
AE, adverse event; TS, Tanner stage.
*Treatment-related AEs are shown in italics.
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subjects. In addition, no clinically meaningful potential
safety trends were noted. Moreover, the safety and
tolerability profile observed in this study was qualitatively
and quantitatively similar to that observed previously in
both adult and pediatric populations.21,26,40
The 2013 and 2015 European Atherosclerosis Society
consensus statements on FH and the clinical guidance from
the National Lipid Association Expert Panel41 recommend
that lipid-lowering therapies should be strongly considered
alongside lifestyle changes in children, starting at 8–
10 years.5,8 This recommendation differs from the 2011
US Integrated Guidelines for the CV Health and Risk
Reduction in Children and Adolescents, which notes that
children ,10 years should not be treated with lipid-
lowering medication unless they have LDL-C levels of
$400 mg/dL (10.36 mmol/L).42
This study is limited by its open-label design, lack of an
active comparator and by the limited number of subjects
who received the 80-mg dose of atorvastatin, which mean
our safety data are too limited to draw any conclusions
regarding this dose. An additional limitation is the lack of
genetic information collated across this cohort of children
with HeFH. However, the study has some notable strengths
such as children as young as 6 years old being enrolled, a
duration of 3 years and the utilization of measures of
growth and maturation.
The results of this study suggest that atorvastatin in
doses of 5–40 mg is effective and can be used safely in
children with HeFH aged as young as 6 years. These
findings together with observations from other studies,
which have demonstrated that atherosclerotic changes are
apparent in children with HeFH before the age of
8 years,12,13 and that statins slow this progression,27,43
highlight the importance of starting statin therapy early inchildren with HeFH.8,42–44 Indeed, atorvastatin is now
approved for use from 6 years in Australia.8
In conclusion, our study demonstrates the favorable
efficacy, safety, and tolerability profile of atorvastatin in
both children as young as 6 years and adolescent subjects,
treated for a period of 3 years.Acknowledgment
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Appendix
Methods
This open-label, multicenter, prospective study was
conducted at 30 centers in Belgium, Canada, Germany,
Greece, Hungary, Italy, Norway, Poland, Russian Federa-
tion, Slovakia, Spain, Switzerland, Turkey, and the United
States.
HeFH genetic testing was conducted using the following
methodologies: DNA was extracted from saliva (collected
in Oragene DNA sample collection kit, DNA Genotek) or
from blood using the QiAmp Blood DNA Mini Kit (Qiagen,
Germany), according to manufacturer instructions. The
promoter region and all the 18 exons and flanking regions
of the LDL-R gene were amplified by polymerase chain
reaction, and exon 26 of the apoB gene was sequenced in an
ABI 3730 DNA analyzer using SANGER methodology
after polymerase chain reaction amplification of the DNA
samples. Sequence analysis was carried out using SeqScape
software, v2.6. Reference sequences for the genes analyzed
were based on the hg19-GRCh37 genome assembly data-
base (LDLR: Ref Seq NM_000527.5 and APOB: Ref Eeq
NM_000384.2). Samples were also tested for large dele-
tions or insertions, using the MLPA—Multiplex Ligase
dependent Probe Amplification kit (MRC, Holland) and
following manufacturer’s instructions.
Flow-mediated dilatation (FMD) measurements were
made using each center’s validated peer-review and pub-
lished FMD protocol. FMD measurements were made at
baseline and at months 6, 12, 18, 24, 30, and 36. The lipid
panel was assessed at screening and at months 1, 2, 3, 6, 12,
18, 24, 30, and 36. FMD data were based on collected
measures (hyperemic and resting diameter) and calculated
as follows: FMD (%) 5 (hyperemic diameter 2 resting
diameter)/resting diameter ! 100.
Results
Flow-mediated dilation
In an effort to measure the effects of low-density
lipoprotein cholesterol (LDL-C) lowering on endothelial
function, we applied the established method of ultrasoni-
cally measured FMD in a part of our study population. A
total of 73 subjects (37 at Tanner stage [TS] 1 and 36 at TS
stage $2) from four centers were included in the FMD
substudy. The FMD profile showed no discernable trends in
either male or female subjects with the mean percentage
dilation exhibiting little change over the duration of this
substudy (Supplemental Fig. 1), possibly due to issues both
in the methodology and the study design. For example, only
a small number of patients took part in this substudy. Also,
it is possible that the methodology used varied between the
four centers leading to inconsistent results. Finally, the
blood vessel walls of the children and adolescents examined
may not have been sufficiently thickened by atherosclerosis
for a beneficial effect of statins to be observed. Additional
studies may be required to evaluate whether treatment with
statins can have an effect on FMD in children and adoles-
cents with familial hypercholesterolemia (FH) and whether
this technique is useful for measuring endothelial dysfunc-
tion and atherosclerosis in children.
Supplemental safety information
The serious adverse events reported by the subjects in
the TS 1 group were myositis (this was not associated with
abnormal CK values and the subject continued taking study
medication), feeling abnormal/syncope, intravascular papil-
lary endothelial hyperplasia, testicular appendage torsion,
hemorrhoids, viral infection, appendicitis (2 subjects),
bipolar disorder, appendix disorder, concussion, abdominal
pain, ulna fracture, and Ewing’s sarcoma. The serious
adverse events reported by the subjects in the TS $2 group
were syncope, limb injury, abdominal pain and vomiting,
suicide attempt, lumbar and thoracic vertebral fracture,
obesity, and type 1 diabetes mellitus.
Supplemental Figure 1 Mean FMD in a subset of subjects over
36 months among children and adolescents with HeFH receiving
atorvastatin therapy. FMD, flow-mediated dilation; HeFH, hetero-
zygous familial hypercholesterolemia.
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Supplemental Table 1 Concomitant medications used in
subjects by TS ($10 total subjects)
Concomitant medication
TS 1 TS $2 Total
139 132 271
Number (%) of subjects
with any concomitant
drug treatment
97 (69.8) 95 (72.0) 192 (70.8)
Paracetamol 46 (33.1) 42 (31.8) 88 (32.5)
Ibuprofen 28 (20.1) 30 (22.7) 58 (21.4)
Amoxicillin 14 (10.1) 9 (6.8) 23 (8.5)
Clavulin 9 (6.5) 7 (5.3) 16 (5.9)
A/H1N1 influenza
pandemic vaccine
9 (6.5) 4 (3.0) 13 (4.8)
Methylphenidate
hydrochloride
7 (5.0) 4 (3.0) 11 (4.1)
Azithromycin 4 (2.8) 7 (5.3) 11 (4.1)
Cetirizine hydrochloride 7 (5.0) 3 (2.3) 10 (3.7)
Clarithromycin 8 (5.8) 2 (1.5) 10 (3.7)
Fluticasone propionate 7 (5.0) 3 (2.3) 10 (3.7)
Salbutamol 7 (5.0) 3 (2.3) 10 (3.7)
TS, Tanner stage.
Supplemental Table 2 The incidence of AEs (all causality) and the most commonly occurring AEs by the dose of maximum duration in
patients at TS 1
Type or category of AE
Dose of maximum duration, n (%) of subjects at TS 1
5 mg
(n 5 15)
10 mg
(n 5 35)
20 mg
(n 5 54)
40 mg
(n 5 30)
80 mg
(n 5 5)
All
(n 5 139)
Adverse event
Subjects with any AEs 12 (80.0) 23 (65.7) 48 (88.9) 25 (83.3) 5 (100) 113 (81.3)
Subjects with serious AEs 2 (13.3) 4 (11.4) 4 (7.4) 3 (10.0) 1 (20.0) 14 (10.1)
Subjects with severe AEs 2 (13.3) 3 (8.6) 2 (3.7) 2 (6.7) 0 9 (6.5)
Subjects who discontinued due to AEs, n (%) 1 (6.7) 1 (2.9) 0 1 (3.3) 1 (20.0) 4 (2.9)
Subjects who had their dose reduced or
temporarily discontinued due to AEs
1 (6.7) 7 (20.0) 12 (12.2) 6 (20.0) 0 26 (18.7)
Most commonly occurring AEs*, n (%)
Nasopharyngitis 2 (13.3) 3 (8.6) 14 (25.9) 6 (20.0) 1 (20.0) 26 (18.7)
Headache 1 (6.7) 6 (17.4) 11 (20.4) 7 (23.3) 0 25 (18.0)
Abdominal pain 1 (6.7) 4 (11.4) 11 (20.4) 4 (13.3) 1 (20.0) 21 (15.1)
Upper respiratory tract infection 2 (13.3) 5 (14.3) 8 (14.8) 5 (16.7) 0 20 (14.4)
Gastroenteritis 0 3 (8.6) 8 (14.8) 6 (20.0) 0 17 (12.2)
Pyrexia 0 3 (8.6) 6 (11.1) 5 (16.7) 1 (20.0) 15 (10.8)
Vomiting 0 2 (5.7) 8 (14.8) 4 (13.3) 1 (20.0) 15 (10.8)
Cough 1 (6.7) 4 (11.4) 6 (11.1) 3 (10.0) 0 14 (10.1)
Pain in extremity 1 (6.7) 1 (2.9) 6 (11.1) 5 (16.7) 1 (20.0) 14 (10.1)
Influenza 1 (6.7) 3 (8.6) 5 (9.3) 4 (13.3) 0 13 (9.4)
Rhinitis 1 (6.7) 1 (2.9) 7 (13.0) 3 (10.0) 1 (20.0) 13 (9.4)
Viral upper respiratory tract infection 0 4 (11.4) 7 (13.0) 1 (3.3) 1 (20.0) 13 (9.4)
Arthralgia 1 (6.7) 2 (5.7) 4 (7.4) 3 (10.0) 0 10 (7.2)
Tonsillitis 0 3 (8.6) 3 (5.6) 3 (10.0) 1 (20.0) 10 (7.2)
Bronchitis 1 (6.7) 2 (5.7) 4 (7.4) 2 (6.7) 0 9 (6.5)
Ear infection 2 (13.3) 2 (5.7) 4 (7.4) 0 1 (20.0) 9 (6.5)
Pharyngitis 0 1 (2.9) 4 (7.4) 4 (13.3) 0 9 (6.5)
Diarrhea 0 2 (5.7) 5 (9.3) 1 (3.3) 0 8 (5.8)
Abdominal pain upper 0 1 (2.9) 2 (3.7) 3 (10.0) 1 (20.0) 7 (5.0)
Respiratory tract infectionit 1 (6.7) 3 (8.6) 1 (1.9) 2 (6.7) 0 7 (5.0)
AE, adverse event; TS, Tanner stage.
Severe AEs are those that interfere significantly with subject’s usual function.
*AEs observed in $5% of all subjects.
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Supplemental Table 3 The incidence of AEs (all causality) and the most commonly occurring AEs by the dose of maximum duration in
patients at TS $2
Type or category of AE
Dose of maximum duration
5 mg
(n 5 8)
10 mg
(n 5 44)
20 mg
(n 5 29)
40 mg
(n 5 48)
80 mg
(n 5 3)
All
(n 5 132)
Adverse event
Subjects with any AEs, n (%) 6 (75.0) 29 (65.9) 25 (86.21) 42 (87.5) 3 (100.0) 105 (79.6)
Subjects with serious AEs, n (%) 1 (12.5) 2 (4.6) 1 (3.5) 3 (6.3) 0 7 (5.3)
Subjects with severe AEs, n (%) 1 (12.5) 4 (9.1) 2 (6.9) 4 (8.3) 0 11 (8.3)
Subjects who discontinued due to AEs, n (%) 0 2 (4.6) 0 0 0 2 (1.5)
Subjects who had their dose reduced
or temporarily discontinued due to AEs, n (%)
0 6 (13.6) 6 (20.7) 8 (16.7) 0
Most commonly occurring AEs*, n (%)
Nasopharyngitis 0 8 (18.2) 8 (27.6) 10 (20.8) 0 26 (19.7)
Headache 0 7 (15.9) 10 (34.5) 8 (16.7) 0 25 (18.9)
Influenza 0 2 (4.6) 3 (10.3) 9 (18.8) 0 14 (10.6)
Pyrexia 1 (12.5) 3 (6.8) 2 (6.9) 7 (14.6) 0 13 (9.9)
Gastroenteritis 0 4 (9.1) 3 (10.3) 5 (10.4) 0 12 (9.1)
Cough 0 4 (9.1) 2 (6.9) 5 (10.4) 0 11 (8.3)
Abdominal pain 1 (12.5) 4 (9.1) 4 (13.8) 1 (2.1) 0 10 (7.6)
Myalgia 0 3 (6.8) 3 (10.3) 4 (8.3) 0 10 (7.6)
Upper respiratory tract infection 0 3 (6.8) 3 (10.3) 4 (8.3) 0 10 (7.6)
Blood creatine phosphokinase increase 0 2 (4.6) 3 (10.3) 3 (6.3) 1 (33.3) 9 (6.8)
Diarrhea 0 2 (4.6) 2 (6.9) 5 (10.4) 0 9 (6.8)
Rhinitis 0 4 (9.1) 1 (3.5) 4 (8.3) 0 9 (6.8)
Nausea 0 4 (9.1) 2 (6.9) 2 (4.2) 0 8 (6.1)
Pharyngitis 0 1 (2.3) 4 (13.8) 2 (4.2) 1 (33.3) 8 (6.1)
Vomiting 0 6 (13.6) 0 2 (4.2) 0 8 (6.1)
AE, adverse event; TS, Tanner stage.
Severe AEs are those that interfere significantly with subject’s usual function.
*AEs observed in $5% of all subjects.
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